Table 6. Change from baseline to 4th month and to 12th month.
| Study population (n = 213) | Ranibizumab (n = 122) | Aflibercept (n = 91) | P | |
|---|---|---|---|---|
| HbA1c | ||||
| Baseline, mean ± SD, % | 7.88 (+/- 1.63) | 7.91 (+/- 1.27) | 7.84 (+/- 2.03) | .230 |
| 4th Month, mean ± SD, % | 7.80 (+/- 1.50) | 7.86 (+/- 1.34) | 7.72 (+/- 1.70) | .319 |
| 12th Month, mean ± SD, % | 7.79 (+/- 1.43) | 7.94 (+/- 1.20) | 7.58 (+/- 1.68) | .060 |
| BCVA | ||||
| Baseline, mean ± SD, logMar | 0.52 (+/- 0.34) | 0.55 (+/- 0.35) | 0.48 (+/- 0.29) | .109 |
| 4th Month, mean ± SD, logMar | 0.40 (+/- 0.31) | 0.41 (+/- 0.34) | 0.40 (+/- 0.27) | .888 |
| 12th Month, mean ± SD, logMar | 0.40 (+/- 0.33) | 0.40 (+/- 0.35) | 0.40 (+/- 0.29) | .864 |
| CMT | ||||
| Baseline, mean ± SD, μm | 456.11 (+/-131.08) | 483.45 (+/- 142.13) | 419.46 (+/- 104.61) | .000 |
| 4th Month, mean ± SD, μm | 374.04 (+/-99.99) | 388.67 (+/- 100.71) | 354.73 (+/- 96.16) | .014 |
| 12th Month, mean ± SD, μm | 372.15 (+/-111.76) | 377.06 (+/- 116.59) | 365.56 (+/- 105.22) | .459 |
| Change, mean ± SD, μm | -83.97 (+/- 150.32) | -106.39 (+/- 166.86 | -53.90 (+/- 119.15) | .011 |
| CMV | ||||
| Baseline, mean ± SD, mm3 | 10.26 (+/- 1.96) | 10.73 (+/- 2.21) | 9.63 (+/- 1.35) | .000 |
| 4th Month, mean ± SD, mm3 | 9.40 (+/- 1.29) | 9.67 (+/- 1.49) | 9.05 (+/- 0.85) | .001 |
| 12th Month, mean ± SD, mm3 | 9.49 (+/- 1.24) | 9.69 (+/- 1.61) | 9.21 (+/- 1.28) | .024 |
| Change, mean ± SD, mm3 | -0.77 (+/- 1.84) | -1.04 (+/- 2.02) | -0.42 (+/- 1.51) | .015 |
(HbA1c: glycosylated haemoglobin, BCVA: best corrected visual acuity, CMT: central macular thickness, CMV: central macular volume)